Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Qu Biologics

Request full access

Restores innate immune function and reverse the chronic inflammation underlying many conditions such as cancer and immune-related disease

Vancouver, CanadaFounded 2007Biotech & Life Sciences

About Qu Biologics

Qu Biologics Inc. is a private, clinical-stage biotechnology company based in Vancouver, Canada, focused on developing treatments for diseases linked to chronic inflammation. Founded in 2007 by Dr. Hal Gunn and Rob Freeman, the company is pioneering a novel immunotherapy platform called Site Specific Immunomodulators (SSIs). Dr. Gunn, who serves as CEO, is a physician-entrepreneur with a long-standing interest in the body's innate healing capacities. His journey began after witnessing a remarkable recovery in a pancreatic cancer patient who developed a severe infection, leading him to hypothesize that activating the innate immune system could combat chronic diseases. Before founding Qu Biologics, Dr. Gunn co-founded InspireHealth, Canada's foremost supportive cancer care center, and he holds a Doctorate of Medicine from the University of British Columbia.

The company's core business revolves around its proprietary SSI platform, which is designed to restore normal immune function in specific organs. Unlike immunotherapies that target a single pathway, SSIs are developed to stimulate and 'train' the body's innate immune system, directing activated immune cells to a targeted organ to resolve the underlying immune dysfunction. The technology is based on the 'hygiene hypothesis,' which links a decline in acute infections to a rise in immune-related diseases. SSIs are composed of components from inactivated bacteria that are typically associated with infections in the target organ, aiming to mimic the beneficial training effects of an infection without causing illness. For example, QBECO, which targets the gastrointestinal tract, is derived from E. coli, while QBKPN targets the lungs and is derived from K. pneumoniae. The treatments are designed for self-administration via subcutaneous injection.

Qu Biologics is a clinical-stage company, generating data through a series of clinical trials rather than commercial revenue. The company serves patients with conditions such as cancer (lung, colon), inflammatory bowel disease (Crohn's disease, ulcerative colitis), and immunosenescence (age-related immune decline). Qu Biologics has completed several Phase 2 clinical trials and has others underway to evaluate the safety and efficacy of its SSI treatments. As a private entity, the firm's operations are financed through equity funding from angel investors, family offices, and high-net-worth individuals, along with non-dilutive funding from grants. The company has raised approximately $29.8M in total funding, including a $12M Series C round in March 2022, to advance its clinical programs and expand its team.

Source: Dealroom company data

At a glance

Status
Operational
Employees
10
Open positions
None listed
Dealroom signal
29.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANT✓Other financing Nov 2023 $293K — Canadian Institutes of Health Research ↗
GRANT✓Other financing Oct 2022 $6.7M — National Research Council Canada ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Qu Biologics website traffic

Latest recorded traffic for Qu Biologics is 2.5K monthly website visits, up 127.3% over the last three months. Qu Biologics's team declined 16.7% over the past year.

Latest monthly visits2.5K 3-month web change+127.3% 1-year team growth-16.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Qu Biologics in the Vancouver ecosystem

Live from Dealroom

The Qu Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • National Research Council Canada
  • Canadian Institutes of Health Research

Series B and later1 investor entered at this stage

  • Asian Capital Alliance

Other known investors3 additional known investors

  • Curitas Ventures
  • Dave Lopez
  • Harmonix
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇦 Canada84.6%
🇨🇴 Colombia7.7%
🇺🇸 United States7.7%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Qu Biologics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Qu Biologics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.